Sentinel Diagnostics Launches Two New Serological Tests To Quickly Assess The Immunoresponse To SARS-CoV-2
AsiaNet 89354
MILAN, May 4, 2021 /PRNewswire=KYODO JBN/ --
To quickly assess the immune response to SARS-CoV-2 of patients and entire
communities, Sentinel Diagnostics - an Italian company focused for more than 35
years on the development and production of In Vitro Diagnostics for the most
advanced Clinical Chemistry, Immunochemistry and Molecular Diagnostics
platforms - announces the launch of two new serological tests for the detection
of total antibodies (IgA, IgG and IgM) to SARS-CoV-2 specific proteins in human
serum: COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab.
The application of these tests would help to identify those individuals who
have correctly developed antibodies after infection and/or vaccination,
supporting the understanding of the degree of diffusion of COVID-19 in the
community and the results of the efforts made by countries for vaccination
campaigns. "The spread of the SARS-CoV-2 pandemic and the current ongoing
vaccination campaigns have raised the need for quick evaluation of the
immunological status of individuals and communities to understand what measures
to adopt in order to avoid spreading of infection, but also to monitor the
immune response after vaccination," explains Marco Buonaguidi, Head of Sales
and Marketing. "We have developed our new quick solution that supports the
continuous monitoring of epidemic to ensure public health decisions delivering
fast results."
Both COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab assays are In
Vitro Diagnostic tests, for quantitative and qualitative analysis with
immunoturbimetric method, designed to process hundreds of results in 1 hour and
thousands in a single day when used on our Sentinel SENTIFIT®270 Analyzer or
other automated analytical platforms. The first kit detects the total
antibodies against the Spike RBD S1 protein, while the second detects the
antibodies against Nucleocapsid (NC) protein.
The new Sentinel Diagnostics assays provide the first results in about 10
minutes. The use of Sentinel COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC
Total Ab would help distinguish vaccinated individuals from naturally infected
ones. The tests can be performed together on the same serum sample or
separately to better fit with laboratory needs.
For more information, visit www.sentineldiagnostics.com.
Logo - https://mma.prnewswire.com/media/1502740/Sentinel_Diagnostics_Logo.jpg
Source: Sentinel Diagnostics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。